Biotech Startups

Modulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders. It uses multiple neurobiology models and computational biology to study neuroimmune mechanisms and discover new therapies for patients affected by neurological disease.

3 investors

Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification. The company serves researchers and developers in therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology.

3 investors

Molecule builds a blockchain-based ecosystem that connects scientists and entrepreneurs working on decentralized science projects, with a focus on AI-driven drug discovery and research funding.

3 investors

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.

3 investors

Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression. The company builds implantable neurotechnology for patients with mental illness and is based in Houston, Texas.

3 investors

Mozza Foods develops casein protein grown in soybeans as an ingredient for the dairy industry, aiming to replace cow-dependent supply chains using existing agricultural infrastructure. The company targets dairy manufacturers with a bioengineered protein ingredient.

3 investors

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX. The company is no longer operating.

3 investors

Mycologics develops natural product-based biofungicides that target soil-borne and foliar fungal diseases in food and feed crops such as corn, sugar beets, and cucurbits. The company positions its products as low-cost alternatives to chemical fungicides for use in agricultural pest management.

3 investors

MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products. The company works with designers, studios, and brands such as Ligne Roset and Cadillac to create finished goods.

3 investors

MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

3 investors

Myoridge develops serum-free cell culture media and optimization services for cell cultivation and regenerative medicine applications. The company provides media formulations, consulting, and in vitro model development support to organizations conducting biotechnology research and cell therapy product development.

3 investors

Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment. The company focuses on discovering novel payloads to address unmet oncology needs.

3 investors

Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.

3 investors

NanoCellect develops microfluidic-based cell sorters that operate at low pressure to sort cells with high viability and reduced shear stress, aimed at scientists and researchers. Its products use disposable, sterile microfluidic cartridges for applications such as single-cell sorting and stem cell research.

3 investors

Nanochon develops Chondrograft, a 3D-printed, off-the-shelf orthopedic implant that is press-fit into damaged knee cartilage to support the body's natural tissue healing. It targets "pre-replacement" patients with focal cartilage defects who need more than temporary relief but are not yet candidates for joint replacement.

3 investors

Nanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.

3 investors

DermaLayr develops a transdermal delivery platform using ultrafine bioactive nanofibres to enable active ingredients to penetrate deeper into skin. The company serves the beauty and skincare industry with a dry active film technology for topical treatments.

3 investors

Nautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.

3 investors

3 investors

Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

3 investors

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.

3 investors

Neuroclues develops eye-tracking technology to identify neurological disorders including Parkinson's, Alzheimer's, and Multiple Sclerosis before symptoms appear, serving clinicians and healthcare practitioners. The company combines hardware, software, and cloud systems to provide biomarkers for early disease detection.

3 investors

NewLeaf develops PPFM (Pink-Pigmented Facultative Methylotroph) microbial technologies for agriculture, offering EPA-registered biofungicide and bioinsecticide products (TS601 and TS201) plus crop-specific biostimulants for growers of corn, soy, cotton, rice and other crops. Its biological BioControl and biostimulant products aim to protect crops from pests and diseases and improve yield.</parameter> <parameter name="founders">[]

3 investors

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor. Its pipeline of first-in-class immuno-oncology assets is aimed at cancer patients with B7-H7 upregulation, including those who do not respond to existing PD-1/L1 inhibitor therapies.

3 investors